Company Profile
Incyte Stock Price, News & Catalysts
- Ticker:
- INCY
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Wilmington, Delaware
Stock performance
117.14 USD (-3.47%)
Close
Last updated: October 1, 2026
18.4B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, INCY closed down 3.47% at $117.14. No new same-company headline was identified in the current news window.
Company overview
Research-Based Biopharmaceutical Company
Incyte discovers, develops, and commercializes medicines across hematology, oncology, and inflammation and autoimmunity. The company has built an internal discovery engine around targeted small molecules and biologics while expanding its commercial footprint through both wholly owned and partnered products.
Hematology Franchise
The hematology business is anchored by Jakafi and Jakafi XR across myelofibrosis, polycythemia vera, and graft-versus-host disease. Monjuvi/Minjuvi and Niktimvo extend the franchise into B-cell lymphoma and chronic graft-versus-host disease, while INCA033989 targets mutant calreticulin in myeloproliferative neoplasms.
Oncology Portfolio
Incyte's oncology portfolio includes Zynyz and Pemazyre as well as clinical candidates targeting KRAS G12D, TGF-beta receptor 2, and CDK2. Development emphasizes biomarker-defined tumors and combinations with established chemotherapy, antibodies, and antiangiogenic agents.
Dermatology and Autoimmune Medicines
Opzelura is a topical JAK inhibitor commercialized for atopic dermatitis and vitiligo, with studies underway in additional inflammatory skin diseases. Povorcitinib, an oral JAK1 inhibitor, is being developed across hidradenitis suppurativa, prurigo nodularis, asthma, and other immune-mediated conditions.
Acquired and Partnered Pipeline
The acquisition of Vega Therapeutics added latarcibart, a once-monthly antibody in Phase 3 development for von Willebrand disease. Incyte also uses collaborations for formulation technology, regional commercialization, and selected pipeline assets, complementing its internally generated programs.
Future catalysts
- Potential U.S. approval and launch of Monjuvi for newly diagnosed diffuse large B-cell lymphoma in the first quarter of 2027.
- Topline Phase 2 data for axatilimab plus ruxolitinib in newly diagnosed chronic graft-versus-host disease in the second half of 2026.
- Presentation of INCB161734 and INCA33890 Phase 1 combination data at ESMO 2026.
- Initiation of a Phase 3 study of INCB123667 in first-line maintenance ovarian cancer in the second half of 2026.
- Phase 3 TRuE-HS1 and TRuE-HS2 topline results for ruxolitinib cream in hidradenitis suppurativa in the fourth quarter of 2026.
- Potential European launch of povorcitinib in late 2026 and potential U.S. approval and launch in the first quarter of 2027.
- Phase 3 STOP-PN1 and STOP-PN2 data for povorcitinib in prurigo nodularis in the fourth quarter of 2026.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Incyte (INCY)?
Incyte (INCY) most recently closed at 117.14 USD, a -3.47% move versus the previous session.
What is the market cap of Incyte (INCY)?
Incyte currently has a market capitalization of 18.4B USD on BioPharmSignal.
What does Incyte do?
Research-Based Biopharmaceutical Company Incyte discovers, develops, and commercializes medicines across hematology, oncology, and inflammation and autoimmunity. The company has built an internal discovery engine around targeted small molecules and biologics while expanding its commercial footprint through both wholly owned and partnered...
On which exchange is INCY stock listed?
Incyte (INCY) is associated with NASDAQ, Wilmington, Delaware, Biopharma.
What is STOP-PN1?
Phase 3 STOP-PN1 and STOP-PN2 data for povorcitinib in prurigo nodularis in the fourth quarter of 2026.
Which conditions is Incyte targeting with STOP-PN1?
Incyte is associated with oncology, cancer therapeutics, inflammatory disease based on its company overview and current catalyst commentary.
How does Incyte describe recent progress with STOP-PN1?
Phase 3 STOP-PN1 and STOP-PN2 data for povorcitinib in prurigo nodularis in the fourth quarter of 2026.
What is STOP-PN2?
Phase 3 STOP-PN1 and STOP-PN2 data for povorcitinib in prurigo nodularis in the fourth quarter of 2026.